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ORIGINAL INVESTIGATION
Inflammatory cytokines in type 2 diabetes 
mellitus as facilitators of hypercoagulation 
and abnormal clot formation
Shehan N. Randeria1, Greig J. A. Thomson1 , Theo A. Nell1 , Timothy Roberts1,2*  and Etheresia Pretorius1* 
Abstract 
Background: The global burden of type 2 diabetes mellitus (T2DM), together with the presence of cardiovascular 
risk in this population, is reaching pandemic levels. A prominent feature of T2DM is chronic and systemic inflamma‑
tion, with the accompanying presence of circulating and dysregulated inflammatory biomarkers; which in turn is 
associated with abnormal clot formation.
Methods: Here, we investigate the correlation between abnormal blood clotting, using thromboelastography (TEG), 
clot ultrastructure using scanning electron microscopy (SEM) and the presence of a dysregulated inflammatory 
cytokine profile, by examining various circulating biomarkers.
Results: Our results show that many biomarkers, across TEG, cytokine and lipid groups, were greatly dysregulated 
in the T2DM sample. Furthermore, our T2DM sample’s coagulation profiles were significantly more hypercoagulable 
when compared to our heathy sample, and ultrastructural analysis confirmed a matted and denser clot structure in 
the T2DM sample.
Conclusions: We suggest that dysregulated circulating molecules may in part be responsible for a hypercoagulable 
state and vascular dysfunction in the T2DM sample. We propose further that a personalized approach could be of 
great value when planning treatment and tracking the patient health status after embarking on a treatment regimes, 
and that looking to novel inflammatory and vascular biomarkers might be crucial.
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Background
The global burden of diabetes was estimated at ~ 420 
million during 2014 and has doubled since 1980 where 
the prevalence was ~ 5% compared to ~ 9% for adults 
diagnosed with type-2 diabetes mellitus (T2DM) [1]. 
Premature mortality rates resulting from T2DM and 
thromboembolic cardiovascular disease, are estimated 
to be as high as 43% in both men and women before the 
age of 70 years [2–5]. A most prominent feature of this 
condition is chronic (low-grade) inflammation, with the 
accompanying presence of circulating and dysregulated 
inflammatory biomarkers. Such a dysregulated circulat-
ing inflammatory marker profile is associated both with 
a hypercoagulable state and hypofibrinolysis [6, 7]. Obe-
sity, which is strongly associated with the prevalence and 
incidence of T2DM, has been shown to induce low grade 
(chronic) inflammation [8–10] and insulin resistance (IR) 
[11, 12]. Chronic multifactorial inflammation originat-
ing mostly from an imbalanced diet and lack of physical 
exercise, contribute towards the development of T2DM, 
and is well-known in known inflammatory disease [13]. 
Therefore, the complications as a result of low-grade 
inflammation and diet in T2DM, include mainly cardio-
vascular disease  (CVD), mainly due to hyperglycaemia, 
and in turn might enhance dysregulated coagulation [2, 
14]. Ultimately, an important determinant behind the 
Open Access
Cardiovascular Diabetology
*Correspondence:  timothy‑roberts@outlook.com; resiap@sun.ac.za 
1 Department of Physiological Sciences, Stellenbosch University, Private 
Bag X1, Matieland 7602, South Africa
Full list of author information is available at the end of the article
Page 2 of 15Randeria et al. Cardiovasc Diabetol           (2019) 18:72 
current global T2DM epidemic is IR in overweight and 
obese individuals [15].
For T2DM patients disease profiling, clinicians typi-
cally measure C-reactive protein (CRP or highly sensitive 
(hs)-CRP), blood lipid profiles and glucose/Hb1Ac levels. 
Measuring CRP and lipid profiles have been shown to 
predict the development of T2DM in non-diabetics irre-
spective of adiposity and IR [16]. Traditionally, chroni-
cally elevated blood glucose concentrations are indicative 
of T2DM risk [15] and both a persistent dysregulated 
blood glucose level and abnormal lipid profile would 
typically confirm T2DM. Type 2 diabetic individuals also 
have a greater risk for cardiovascular complications [17]. 
Other measures such as blood pressure and BMI would 
typically also be taken into consideration when a treat-
ment regime is planned. There is a plethora of evidence 
describing the correlation between CRP, monocyte che-
moattractant protein-1 (MCP-1), tumor necrosis factor-α 
(TNF-α) and IL-1β in obese T2DM patients [18, 19].
Due to the pandemic nature of T2DM, and increased 
cardiovascular risk, there is a growing need for innova-
tive strategies to change our approach in both the iden-
tification and successful treatment of such individuals. 
A much more focussed approach is therefore needed in 
patient care of T2DM, by regularly assessing systemic 
inflammation and cardiovascular risk in this population, 
and one such approach would be to turn to the use of cir-
culating biomarkers to track disease progression, as well 
as medication effectiveness.
Inflammatory (circulating) biomarkers, when dys-
regulated, have been identified as key players in causing 
abnormal clot formation (see Additional file  1: Tables 
S1 and S2, for a summary of inflammatory biomarkers 
as well as their role in blood dysregulated blood clotting 
(both aberrant hypercoagulation and hypofibrinolysis) 
both in disease and experimental inquisition.
Mutie et al. [15] argue that the emergence of biomarker 
technologies has allowed more targeted therapeutic 
strategies (precision medicine) for diabetes prevention; 
however, currently, the use of such technologies are 
largely confined to pharmacotherapy. Although precision 
diabetes medicine is confined to pharmacotherapy, using 
biomarkers to personalise lifestyle recommendations, 
in T2DM treatment is becoming a real possibility [20]. 
Both personalised and precision medicine approaches in 
T2DM should therefore be an important and urgent con-
sideration, as many individuals with T2DM have multiple 
(cardiovascular) comorbidities [21].
The current paper investigates hypercoagulation, using 
thromboelastography of platelet poor plasma (PPP), and 
PPP clot ultrastructure, using clots prepared with throm-
bin, and viewed with a scanning electron microscope in 
healthy and T2DM individuals. Furthermore, we study 
levels of 20 circulating cytokine biomarkers and how 
they might differ between healthy individuals, and indi-
viduals with T2DM. We also look at  intercellular adhe-
sion molecule-1 (ICAM-1), vascular adhesion molecule-1 
(VCAM-1), and serum amyloid A (SAA). The increase in 
the concentrations of (soluble) sVCAM-1 and sICAM-1 
reflects the degree of endothelial damage, and ultimately 
may impact on cardiovascular risk if it is chronically 
increased. Levels of  SAA, which is a major acute phase 
protein in humans, are increased up to 1000-fold upon 
infection, trauma, cancer or other inflammatory events, 
and it plays a key role in regulating the inflammatory 
response [22]. Dysregulation of the circulating cytokines 
that we measure in this paper, are also closely linked to 
dysregulation of sICAM-1, sVCAM-1 and SAA. The pro-
inflammatory cytokines we included in this study, have 
also been associated with platelet (hyper) activation, as 
well as erythrocyte dysfunction, while CRP dysregula-
tion is directly linked to dysregulation of some of these 
molecules, and a strong indication of systemic inflam-
mation. CRP is a part of the member of the pentraxin 
family which are pattern recognition proteins that play 
an integral role in the innate immune system [23]. When 
secreted from the liver in response to IL-6, CRP forms an 
annular pentameric protein shape which then circulates 
throughout the body in blood plasma [24]. Interleukin-6 
(IL-6) and its downstream product, CRP, are therefore 
both well-known inflammatory molecules. Importantly, 
due to an increase in  IL-6,  circulaitng CRP levels can 
increase up to 1000 times during disease or inflamma-
tion [25]. We also included analysis of levels of HbA1c 
and lipid profiles, as these are markers that can confirm 
hyperglycemia and systemic inflammation.
The following paragraphs briefly discuss some of the 
main interactions between circulating cytokines and 
sICAM-1, sVCAM-1 and SAA. ICAM-1 is referred to as 
Cluster of Differentiation 54(CD54), is a protein encoded 
by the ICAM1 gene which encodes for a glycoprotein 
located on the cell surface of endothelial cells, as well as 
cells of the immune system, such as leukocytes [26, 27]. 
These cells continuously present with ICAM-1 at low 
levels on their cell membranes, however, when stimu-
lated via TNF-α [28, 29], IL-1β, lipopolysaccharide (LPS) 
[30] and the presence of reactive oxygen species (ROS) 
[31], ICAM-1 concentrations greatly increase. ICAM-1 
levels have been found to be significantly elevated in 
T2DM [32], and elevated ICAM-1 may be as a result of 
elevated TNF-α and IL-1β found in T2DM. However, the 
increased ICAM-1 may influence T2DM pathogenesis 
via the binding of monocytes/leukocytes to activated vas-
cular endothelium preceding macrophage and foam cell 
development [33], a crucial event potentially resulting in 
T2DM.
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VCAM-1, otherwise known as cluster of differentia-
tion 106 (CD106) is a 90-kDa glycoprotein encoded by 
the VCAM-1 gene [34], may also be of importance in 
inflammation. VCAM-1 expression similar to ICAM-
1, is activated and expressed on the cell membrane of 
endothelial cells [35] in the presence of various pro-
inflammatory cytokines such as TNF-α as well as the 
presence of ROS [36]. When stimulated by circulating 
inflammatory cytokines, various ligands bind to the 
externalised VCAM-1, causing leukocyte to endothelial 
cell binding which starts a cascade effect whereby end-
ing in VCAM-1-dependent leukocyte trans-endothelial 
migration [37]. VCAM-1 is also significantly elevated in 
T2DM [38, 39] and may be one of the leading causes of 
the abnormal endothelial function and activation that 
occurs in T2DM [40, 41]. CRP levels are significantly 
elevated in T2DM and is a strong biomarker for T2DM 
disease progression and management [42]. SAA pres-
ence is also associated with the pathogenesis of chronic 
inflammatory diseases, such as T2DM, as well as ath-
erosclerosis [43, 44].
Platelet (dys)function and both ICAM-1 and 
VCAM-1 are also closely linked. Platelet activation and 
endothelial damage play essential roles in atherosclero-
sis and thrombin-activated  platelet-derived exosomes 
regulate endothelial  cell  expression of  ICAM-1 [45]. 
Proteins that are essential for platelet adhesion include 
P-selectin, von Willebrand factor (vWF), and ICAM-1 
[45]. During activation, platelets release thrombox-
ane A2 (TXA2), which may also bind to receptors on 
platelet membranes. Also binding of locally produced 
TXA2  to thromboxane receptors on endothelial cells 
causes upregulation of ICAM-1 on the cell surface 
[46]. P-selectin mediates platelet rolling on vascular 
wall endothelial cells [47], furthermore von Willebrand 
factor (vWF) is required for platelet adhesion through 
the platelet receptor GPIbα, and ICAM-1 has been 
reported to mediate the platelet receptor GPIIb/IIIa-
dependent bridging mechanism through fibrinogen [48, 
49]. Another platelet receptor of interest if GPVI, which 
is a collagen receptor on platelets, and it is known that 
collagen is exposed from endothelial cells, in cardiovas-
cular diseases, and conditions like T2DM. It has been 
found that there is a positive correlation between a dys-
regulation between surface expression of platelet GPVI 
and with the level of  ICAM-1 in endothelial  cells  in 
disease [50]. Furthermore, platelets tether and roll on 
P-selectin presented on activated endothelium via 
P-selectin GP ligand‐1 (PSGL)-1 and GPlb, and arrest 
via GPIIb–IIIa and fibronectin on endothelial αvβ3 and 
ICAM-1 [46]. Platelets constitute the main source of 
soluble CD40 ligand (sCD40L), expressed on the plate-
let surface under basal conditions and additionally 
translocates to the plasma membrane upon activation. 
sCD40L induces endothelial upregulation of ICAM‐1, 
VCAM‐1, and E‐selectin, and thus supports leukocyte 
recruitment.
Serum amyloid A (SAA) is a generic term for a highly 
conserved family of acute-phase apolipoproteins syn-
thesised by the liver [43, 51]. The SAA molecules can 
be divided into two groups, namely the acute phase 
SAAs that associate with HDL during inflammation; 
and constitutive SAA, including human SAA4 [52]. 
Human apo-SAA is a 104 amino acid polypeptide that 
circulates in plasma bound to high density lipopro-
tein-3 (HDL3) [53]. However, SAA has an important 
effect on HDL structure and function during inflam-
mation, as the majority of SAA is an apolipoprotein of 
high-density lipoprotein HDL [54, 55]. During acute 
inflammation, SAA secreted from the liver displaces 
apolipoprotein A-I bound to HDL, with each HDL 
particle being able to bind and carry several copies of 
SAA [56], thus becoming the major apolipoprotein of 
circulating HDL3 [43]. Acute-phase SAA also modi-
fies the biological effects of HDL-C in several condi-
tions [57]. Depending on the extent of inflammation, it 
has been seen that SAA may increase up to 1000-fold, 
compared to those in the non-inflammatory state [43]. 
Consequently, SAA is a well-established (and potent) 
biomarker for infection and sepsis [58–60]. However, 
increased SAA is also an important plasma biomarker 
for predicting future cardiovascular events, and is asso-
ciated with an increase in thrombotic risk [61, 62] as it 
is an active participant in the early atherogenic process 
[63].
CRP is also a known (hyper) activating ligand via plate-
let receptors and various platelet receptors form com-
plexes on ligand binding, including GPVI with FcRγ 
(chain) after fibrin (ogen) [64–67], collagen, CRP and 
thrombin binding [68]. After CRP binds to the GPVI/
FcRγ (chain) complex, a cascade follows, resulting in 
shedding by metalloproteases such as a-disintegrin-and-
metalloproteinase 10 (ADAM10) [69]. SAA may also 
cause platelet (hyper) activation. We established that 
free SAA, added at low physiological levels (30 µg mL−1), 
representing a modest acute phase response, caused red 
blood cell agglutination, platelet activation and aggre-
gation, but without platelet spreading [70]. It was sug-
gested that the highly lipophilic SAA interacts within the 
platelet cell surface phospholipids (analogous to HDL) to 
produce these effects. The correlations between vascular 
injury, circulating dysregulated cytokines and hyperco-
agulation may therefore be of great importance and point 
to greater cardiovascular risk in T2DM, and might be 
used to track disease severity for a more individualized 
approach in T2DM care.
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Material and materials
Ethics, consent and permissions
The study received ethical clearance from the Health 
Research Ethics Committee (HREC) of Stellenbosch Uni-
versity (South Africa) (approval number N17/01/008_
RECIP_UP.298/2016: E Pretorius) and S18/02/036: G 
Thomson and E Pretorius. Prior to the commencement of 
the study, all volunteers were informed of procedures and 
data collection. Written informed consent was obtained 
from all participants followed by whole blood sampling 
in citrated tubes. All participants received a unique num-
ber that was used to ensure confidentiality throughout 
the study. All investigators were certified in Good Clini-
cal Practice and ethical codes of conduct.
Study design, setting and study population
A cross-sectional design was followed in collaboration 
with an endocrinologist and physician, who provided 
whole blood (WB) from T2DM private patients.
Healthy control sample
Whole blood from healthy controls were collected by a 
Health Professions Council of South Africa (HPCSA) 
registered Medical Biological Scientist and phleboto-
mist (MW: 0010782) at the Department of Physiological 
Sciences, Stellenbosch University. The total study popu-
lation consisted of n = 87 volunteers (n = 46 healthy con-
trols, and n = 41 T2DM patients), from which the 20-Plex 
cytokine analysis, thromboelastography, lipogram and 
V-Plex vascular injury analysis were conducted.
Type 2 diabetes mellitus sample
Whole-blood samples were also collected from individu-
als diagnosed with T2DM and cardiovascular disease at 
least 3 months prior to screening and without any clini-
cal indication of infection (Society for Endocrinology, 
Metabolism and Diabetes of South Africa (SEMSDA) 
guidelines based on American Diabetes Association 
(ADA) criteria). Diabetic volunteers were recruited with 
the following inclusion criteria: (i) a confirmed diagno-
sis of T2DM with cardiovascular disease (ii) males and 
females older than 35  years. Similarly, healthy controls 
were included if they were (iii) non-smokers, (iv) not on 
any contraceptives, (v) not pregnant and/or lactating. 
Participants who were unable to provide written con-
sent were excluded from the study. To limit and exclude 
confounding factors, both healthy and diabetic volun-
teers were only included if they are not diagnosed with 
tuberculosis, human immunodeficiency virus (HIV) 
or any malignancies. The inclusion criteria for healthy 
age-matched volunteers included: (i) no use of chronic 
medication (ii) no prior history of thrombotic disease or 
inflammatory conditions (iii) non-smokers, (iv) not on 
any chronic antiplatelet therapy/anticoagulant medica-
tion or any contraceptive/hormone replacement ther-
apy (v) were not pregnant and/or lactating. Participants 
who were unable to provide written consent were also 
excluded from the study.
Collection of whole blood (WB) and preparation of platelet 
poor plasma (PPP) samples from healthy controls 
and T2DM patients
Whole blood from heathy controls and T2DM patients 
were collected using sterile sampling techniques in cit-
rate and ethylenediaminetetraacetic acid (EDTA) tubes, 
as well as serum separating tubes (SST) that were kept 
at room temperature (22  °C) for 30  min. Platelet poor 
plasma (PPP) were prepared from citrate tubes that were 
centrifuged at 3000×g for 10  min at room temperature 
(∼ 22  °C). The PPP was subsequently aliquotted into 
labelled 1.5  mL Eppendorf tubes, and stored at − 80  °C 
until laboratory analysis. EDTA whole blood and SST 
were analysed by the local PathCare laboratory (Stellen-
bosch) for glycosylated haemoglobin (HbA1c).
Thromboelastography (TEG) of platelet poor plasma (PPP)
Clot kinetics/property studies was performed using 
Thromboelastography (TEG) (Thromboelastograph 5000 
Hemostasis Analyzer System), on both control (n = 23) 
and T2DM (n = 25) PPP samples. After collection and 
PPP preparation, all samples were stored at − 80 °C until 
TEG analysis. At the time of TEG analysis, PPP sam-
ples were thawed from − 80  °C to room temperature. 
Once samples were completely thawed, 340  μL of PPP 
were placed in a disposable TEG cup to which 20  μL 
of 0.2  mol  L−1  CaCl2 was added.  CaCl2 is necessary to 
reverse the effect of the sodium citrate anticoagulant in 
the collection tube (i.e. recalcification of blood) and con-
sequently initiate coagulation. The samples were then 
loaded in the TEG for analysis. The clot parameters that 
were assessed are presented in Table 1.
Scanning electron microscopy
In order to form the fibrin clots, 5 µL of purified throm-
bin (provided by the South African National Blood Ser-
vice) was added into 10 µL of PPP from healthy controls 
(n = 10) and T2DM (n = 10) individuals on 10 mm round 
glass slides. Immediately after adding the thrombin, the 
glass slides were washed with 10× Gibco™ PBS (phos-
phate-buffered saline), pH 7.4 (ThermoFisher Scientific, 
11594516) before fixing with 4% paraformaldehyde for a 
minimum of 30  min. Once fixed, samples were washed 
3 × 3 min with PBS before a further 30-min fixation step 
in 1% osmium tetroxide (Sigma-Aldrich, 75632). A final 
3 × 3 min PBS wash step was performed before samples 
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were serially dehydrated in ethanol (30%, 50%, 70%, 90% 
and 100%) with a final 30-min dehydration step occurring 
using 99.9% hexamethyldisilazane (HMDS)  ReagentPlus® 
(Sigma-Aldrich, 379212). Samples were left in a fume 
hood to air-dry overnight before being mounted onto a 
microscope slide covered in double sided carbon tape. 
Samples were then carbon coated before being imaged 
on Zeiss MERLIN™ field emission scanning microscope 
located in the Central Analytical Facility (CAF) Electron 
Microbeam Unit, Stellenbosch University in order to 
determine fibrin(ogen) ultrastructure. All Micrographs 
were captured using the high resolution InLens capabili-
ties at 1 kV.
20‑Plex cytokine analysis
Stored PPP samples from control (n = 23) and T2DM 
(n = 25) volunteers were transferred from − 80 to − 20 °C 
24 h prior to multiplex analysis. The samples were ana-
lysed in duplicate by means of Invitrogen’s Inflammation 
20-Plex Human ProcartaPlex™ Panel (#EPX200-12185-
901) and read on the Bio-Plex® 200 system (Bio-Rad, 
2016). The data is expressed in pg mL−1. See Table 2 for 
the list of pro-and anti-inflammatory cytokines that were 
analysed.
V‑Plex vascular injury analysis
This ELISA measures sICAM-1, sVCAM-1, SAA and 
CRP. Stored PPP samples from control (n = 36) and 
T2DM (n = 38) volunteers were transferred from − 80 
to − 20 °C 24 h prior to multiplex analysis. The samples 
were analysed in duplicate by means of Meso Scale Dis-
cover Vascular Injury Panel 2 (human) Kits (catalogue 
number: K15198D-1) and read on the MSD Discovery 
Workbench 4 machine. The data is expressed in pg mL−1.
Table 1 Thromboelastography clot parameters for WB and PPP
Parameters Explanation
R value: reaction time; measured in minutes Time of latency from start of test to initial fibrin formation (amplitude of 
2 mm); i.e. initiation time
K value: kinetics; measured in minutes Time taken to achieve a certain level of clot strength (amplitude of 20 mm); 
i.e. amplification
Angle (Α/Alpha): slope between the traces represented by R and K; 
measured in degrees
The angle measures the speed at which fibrin build up and cross linking 
takes place, hence assesses the rate of clot formation; i.e. thrombin burst
Maximal amplitude (MA): measured in mm Maximum strength/stiffness of clot. Reflects the ultimate strength of the 
fibrin clot, i.e. overall stability of the clot
Maximum rate of thrombus generation (MRTG): measured in 
Dyn cm−2 s−1
The maximum velocity of clot growth observed or maximum rate of throm‑
bus generation using G, where G is the elastic modulus strength of the 
thrombus in dynes per  cm−2
Time to maximum rate of thrombus generation (TMRTG): measured in 
minutes
The time interval observed before the maximum speed of the clot growth
Total thrombus generation (TTG): measured in Dyn cm−2 The clot strength: the amount of total resistance (to movement of the cup 
and pin) generated during clot formation. This is the total area under 
the velocity curve during clot growth, representing the amount of clot 
strength generated during clot growth
Coagulation index (CI) Overall assessment of coagulability
Table 2 List of  pro- and  anti-inflammatory biomarkers 
analyses with 20-plex multiplex kit
Anti‑inflammatory biomarkers
 IFN‑α Interferon‑alpha
 IL‑10 Interleukin‑10
 IL‑13 Interleukin‑13
 IL‑4 Interleukin‑4
Pro‑inflammatory biomarkers
 E‑Selectin E‑Selectin
 GM‑CSF Granulocyte‑macrophage colony‑stimulating factor
 IFN‑γ Interferon‑gamma
 IL‑1α Interleukin‑1 alpha
 IL‑1β Interleukin‑1 beta
 IL‑12p70 Interleukin‑12p70
 IL‑17A Interleukin‑17A
 IL‑6 Interleukin‑6
 IL‑8 Interleukin‑8
 IP‑10 Interferon gamma‑induced protein‑10
 MCP‑1 Monocyte chemoattractant protein‑1
 MIP‑1α macrophage inflammatory protein‑1 alpha
 MIP‑1β macrophage inflammatory protein‑1 beta
 P‑Selectin P‑Selectin
 sICAM‑1 Soluble intercellular adhesion molecule‑1
 TNF‑α Tumor necrosis factor‑alpha
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Blood lipid analysis
Blood lipids of PPP samples from control (n = 23) and 
T2DM (n = 25) volunteers were analysed using the Car-
dioChek Plus Professional Cholesterol/Glucose Analyzer 
(CardioChek Version 1.09, Polymer Technology Systems, 
United States of America). Total cholesterol (TC), LDL 
cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides (TG) and non-high-density lipoprotein 
(non-HDL) were measured, and TC/HDL ratio was cal-
culated as a marker of cardiovascular disease (CVD) risk.
Statistical analysis
All statistical analyses were performed using R version 
3.5.3 and the built-in glm package. An age and gender 
adjusted logistic regression model was fit to both the 
main and expanded vascular injury datasets. Odds ratios 
(OR) and 95% confidence intervals, calculated using pro-
filing, are reported. Mann–Whitney non-parametric tests 
were also performed, and P-values reported alongside 
logistic OR values. P-values of < 0.05 were accepted as 
statistically significant.
Results
Demographic data including age, gender and medication 
used for typical comorbidities of T2DM patients were 
recorded by the medical professional on-hand on the day 
of blood sampling at the clinic. Similar demographic data 
for healthy controls were recorded prior to blood sam-
pling (refer to Table 3 for sample demographics and data 
on medication usage) and TEG results of PPP samples 
are shown in Table 4.
The results of the TEG analysis showed significant 
differences between the populations for six of the eight 
assessed parameters (Table  4, final column) and strong 
associations based on the adjusted logistic model in four 
of the parameters (4th column).
It is important to note that a subset of our T2DM sam-
ples were on anticoagulant medication, such as heparin 
Table 3 Sample demographics of study population, healthy and diabetic, and medication profile of diabetic volunteers
Data expressed as mean ± SEM. No significant correlation was observed between age and HbA1c between the healthy and diabetic samples (Spearman-test) of 
both 20-Plex (and V-Plex analysis. Medications prescribed and used by diabetic volunteers were recorded, where n is the number of diabetic individuals on specific 
medication. Medication prescribed for hyperglycaemia included; Diamacron, Diaglucide Metformin, Diaphage, Pioglitazone, Galvus and insulin injections (Optisulin, 
Actraphane, Protaphane, Novomix, Apidra, Lantus, Actrapid,  LEVEMIR®, Humulin). Medication prescribed for blood pressure regulation included; Zartan, Ridaq, 
Coversyl, Amlodipine, Pritor,  LASIX® Retard, Ciplavasc, Adco-Zetomax, Indapamide, Carvedilol, Carloc, Amloc Tareg, Adalat, Ciplazar, Spiractin, Irbesartan, Verahexal 
SR. Medication prescribed for cholesterol regulation included; Simvas, Adco Simvastatintatin, Atorvastatin, Vusor, Aspavor, Bezafibrate.; anticoagulant medication 
consisted of; Xarelto, Clexane, Aspirin, Heparin, Clopidogrel, Clexane, Ecotrin, novel oral anticoagulants
(a) Sample demographics of 20‑Plex cytokine analysis, thromboelastography and lipogram analysis, healthy (n = 23) and diabetic (n = 25) 
volunteers
Healthy individuals (n = 23) Diabetic individuals (n = 25) P‑values
Gender Male (n = 14) Male (n = 13)
Female (n = 9) Female (n = 12)
Age (years) 55.30 ± 3.59 59.75 ± 3.07
HbA1c (%) 5.43 ± 0.10 9.05 ± 0.58 < 0.0001
Diabetic medication
 Hyperglycaemia medication – n = 17 (68.00%)
 Hypertension medication – n = 16 (64.00%)
 Hyperlipidaemia medication – n = 9 (36.00%)
 Anticoagulant medication – n = 12 (48.00%)
(b) Sample demographics of V‑Plex vascular injury analysis, healthy (n = 36) and diabetic (n = 38) volunteers
Healthy individuals (n = 36) Diabetic individuals (n = 38) P‑values
Gender Male (n = 16) Male (n = 19)
Female (n = 20) Female (n = 19)
Age (years) 58.11 ± 10.98 64.58 ± 12.42
HbA1c (%) 5.25 ± 0.09 8.96 ± 0.46 < 0.0001
Diabetic medication
 Hyperglycaemia medication – n = 30 (83.33%)
 Hypertension medication – n = 25 (69.44%)
 Hyperlipidaemia medication – n = 18 (50.00%)
 Anticoagulant medication – n = 19 (52.78%)
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and aspirin (see Table 3). Despite this, the diabetic indi-
viduals showed a significantly increased rate of clot for-
mation (R-value), the initial rate of thrombus formation, 
as well as the K-value, which indicates the clot kinetics. 
Furthermore, in comparison to the healthy control group 
the T2DM individuals presented with a significantly ele-
vated alpha angle (A angle), maximum amplitude (MA), 
maximal rate of thrombus generation (MRTG) as well 
total thrombus generation (TTG) values. This significant 
difference indicates that the clots formed faster in the 
diabetic sample with an overall hypercoagulability that is 
aligned with previous research [13, 71–73].
To further elucidate what contributes towards the 
altered TEG results in T2DM individuals (n = 10) com-
pared to controls (n = 10), SEM was used to visualise 
fibrin ultrastructure. Figure  1 displays representative 
Table 4 Thromboelastography results of eight viscoelastic parameters assessing coagulation efficiency in naïve platelet 
poor plasma samples of healthy (n = 23) and T2DM (n = 25) volunteers
Summary statistics are given as median and IQR. Significant differences are shown in italics for both models
TEG clot parameters Controls (n = 23) T2DM (n = 25) Adjusted OR (95% CI) Mann–
Whitney 
P‑value
R‑value (min) 9.6 [7.4 to 12.3] 7.5 [5.8 to 9.5] 0.787 (0.616, 0.969) 0.032
K‑value (min) 3.75 [2.7 to 5.35] 2.15 [1.8 to 3.1] 0.765 (0.538, 1.03) 0.011
A angle (°) 61 [55.7 to 66.4] 68.1 [61.6 to 70.7] 1.06 (0.966, 1.17) 0.060
MA (mm) 23 [20.2 to 27.5] 30.3 [24.7 to 36.5] 1.12 (1.03, 1.25) 0.011
MRTG (Dyn cm−2 s−1) 3.25 [2.72 to 4.6] 5.45 [3.5 to 7.] 1.59 (1.14, 2.39) 0.014
TMRTG (min) 11.5 [8.5 to 14.7] 8.83 [7.5 to 12.2] 0.867 (0.714, 1.03) 0.100
TTG (Dyn cm−2) 149.4 [127 to 191] 218 [165 to 288] 1.01 (1, 1.02) 0.011
CI − 4.55 [− 4.9 to − 4] − 3.3 [− 4.1 to − 2.3] 3.44 (1.55, 10.8) 0.006
Fig. 1 Representative fibrin clot structure of a control (A) versus a T2DM individual (B–D)
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images of fibrin clots formed from both control and dia-
betics individuals imaged at 5000- and 10,000-times 
machine magnification. Through qualitative analysis, it is 
evident to see that aberrant fibrin clots form in diabetic 
samples as these clots have fibrin fibres with a greater 
diameter, multiple fibres meshing together resulting in 
significantly fewer open spaces between fibres as well 
as the formation of “dense matted deposits” within the 
fibrin clots. All of which result in a stronger more sta-
ble clots which was concurrently observed in the TEG 
analysis.
Tables 5 and 6 contain multiplex cytokine and V-Plex 
vascular injury profile analyses respectively. Note that 
the vascular injury profile population was a super-set of 
the cytokine profile population. One can observe many 
statistically significant differences across the anti-inflam-
matory, pro-inflammatory and vascular injury marker 
Table 5 Anti-inflammatory and pro-inflammatory cytokine profiles and results for healthy and T2DM volunteers
Summary statistics are given as median and [IQR]. Significant differences are shown in italics for both models
Multiplex cytokine results
Cytokines (pg mL−1) Healthy (n = 23) T2DM (n = 25) Adjusted OR (95% CI) Mann–
Whitney 
P‑value
Anti‑inflammatory markers
 IFN‑α 1.35 [0.74–1.63] 2.28 [1.94–2.49] 1.03 (0.75, 1.45) 0.003
 IL‑10 2.74 [1.89–5.29] 9.6 [4.62–16.27] 1.17 (1.05, 1.36) 0.0002
 IL‑13 2.25 [0.665–7.03] 5.75 [2.56–10.01] 1.03 (0.93, 1.15) 0.045
 IL‑4 7.09 [2.3–20.6] 29.63 [15.3–78.5] 1.01 (1, 1.03) 0.004
Pro‑inflammatory markers
 E‑Selectin 25,885 [19,418–30,622] 24,782 [18,633–35,779] 1 (1, 1) 0.902
 GM‑CSF 0.001 [0.001–18] 29.18 [15.61–60] 1.02 (1, 1.04) 0.001
 IFN‑γ 4.12 [0.001–12.6] 12.03 [7.1–19.3] 1.02 (0.98, 1.08) 0.007
 IL‑1α 3.49 [2.45–5.2] 11.33 [3.6–24.9] 1.12 (1.04, 1.23) 0.003
 IL‑1β 16.47 [11.4–30.3] 48.98 [33.8–76.6] 1.02 (1, 1.05) 0.00005
 IL‑12p70 12.03 [6.7–15.4] 22.92 [16.4–30.8] 1.16 (1.06, 1.3) 0.00015
 IL‑17A 0.001 [0.001–0.97] 4.11 [1.05–8.47] 1.09 (0.99, 1.24) 0.0005
 IL‑6 8.43 [0.44–21.18] 239.41 [31–1018] 1 (1, 1.01) 0.00005
 IL‑8 1.33 [0.001–15.6] 36.32 [3.83–69.5] 1.02 (1, 1.04) 0.003
 IP‑10 18.12 [15.2–27.1] 30.8 [23.0–149.6] 1.01 (1, 1.03) 0.005
 MCP‑1 39.98 [24.8–54.4] 65.3 [43.4–134.2] 1.04 (1.02, 1.08) 0.0002
 MIP‑1α 20.94 [4.31–70.7] 63.82 [14.7–108] 1.01 (1, 1.02) 0.083
 MIP‑1β 39.9 [20.7–424.6] 317.1 [65.2–565.4] 1 (1, 1) 0.016
 P‑Selectin 9080 [6318–12,792] 11,967 [9626–16,135] 1 (1, 1) 0.03
 sICAM‑1 39,140 [27,732–59,821] 47,253 [29,219–58,020] 1 (1, 1) 0.79
 TNF‑α 86.3 [68.9–121.5] 161.7 [98.6–197.5] 1.01 (1, 1.03) 0.012
Table 6 V-Plex vascular injury profiles and results for healthy and T2DM volunteers
Summary statistics are given as median and [IQR]. Significant differences are shown in italics for both models
V‑Plex vascular injury results
Biomarker (pg mL−1) Healthy (n = 36) T2DM (n = 39) Adjusted OR (95% CI) Mann–
Whitney 
P‑value
CRP 1113 [550–2373] 7166 [1749–38,086] 1.23 (1.09, 1.5) < 0.0001
SAA 1532 [807–2876] 8433 [2527–91,382] 1.02 (1.01, 1.05) < 0.0001
sICAM‑1 312 [266–357] 367 [300–438] 447 (4.69,121,580) 0.009
sVCAM‑1 387 [327–451] 472 [383–552] 71 (1.55, 9787) 0.004
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groups. As with the TEG parameters we see the non-
parametric test identifies a (strictly) larger set of param-
eters as significant, with differences between the models 
explain by outliers in the control group.
Platelet poor plasma lipid levels are shown in Table 7. 
Healthy controls exhibited significantly higher HDL 
cholesterol levels compared to T2DM individuals 
(OR = 0.114). An important consideration is that a 
subset of our T2DM samples were on lipid-lowering 
medication (statins) (see Table  3). Conversely, TG con-
centrations were significantly higher in the diabetic group 
(OR = 8.34). A trend towards statistical significance was 
apparent for both TC and LDL, favouring higher levels in 
healthy individuals relative to diabetes patients.
The differences between the logistic and non-paramet-
ric test significance results (also present in the unadjusted 
fit) are due to the presence of significant outliers, often 
in the control group, leading to weaker logistic trends. 
These outliers can be seen in the box and whisker plots 
in Fig. 2 (IL-6 is a particularly illustrative example). Both 
models are presented here in order to illustrate both the 
presence of population differences and regressive trends 
and finally to highlight consistent parameters across mul-
tiple techniques. Future studies on a larger population 
sizes should attempt to model the outlier behaviour, par-
ticularly with regards to outliers in the control popula-
tion, using a multi-variate model.
Figures 3 and 4 present lattice plots that illustrated the 
distribution of, and correlations between, the significant 
Table 7 Platelet poor plasma blood lipid profile of healthy and T2DM volunteers
Summary statistics are given as median and IQR. Significant differences are shown in italics for both models
Lipid profile results
Lipogram parameters 
(mmol L−1)
Healthy (n = 23) T2DM (n = 25) Adjusted OR (95% CI) Mann–
Whitney 
P‑value
TC 4.19 [3.66–4.79] 3.83 [3.11–4.3] 0.524 (0.223, 1.08) 0.09
HDL 1.74 [1.57–1.91] 1.44 [1.32–1.71] 0.114 (0.012, 0.64) 0.0047
TG 1.05 [0.81–1.27] 1.29 [1.025–1.65] 8.34 (1.55, 64.3) 0.0139
LDL 2.14 [1.71–2.36] 1.65 [1.29–1.97] 0.419 (0.128, 1.11) 0.07
Non‑HDL 2.51 [2.12–2.88] 2.34 [1.88–2.56] 0.55 (0.159, 1.7) 0.35
Fig. 2 Box and whisker plots for highlighted parameters for healthy (left box) and T2DM populations (right box). Notice the presence of strong 
outliers, such as the IL‑6 healthy group outlier
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parameters. One can observe some strong correlations 
between parameters both within and between parameter 
groups. One notable example, as shown in Fig. 5, is the 
strong correlation between CRP and SAA and sICAM. 
This correlation is of great importance, as it shows a fun-
damental relationship between the presence of systemic 
inflammation, as measured with CRP, and vascular injury, 
as measured with sICAM. It is known that endothelium 
overlying atherosclerotic lesions expresses both ICAM-1 
(and also VCAM-1 and P-selectin, which are both signifi-
cantly upregulated in our T2DM sample) [74]. It is also 
known that ICAM-1, is expressed on endothelium in 
regions not prone to plaque development.
Discussion
Analysis of viscoelastic parameters measured by TEG in 
PPP of control and T2DM individuals showed signifi-
cant differences between the two groups. Importantly, a 
decrease clot reaction time (R-value) and decreased clot 
kinetics (K-value) was observed in the T2DM samples 
indicating an accelerated initial rate of thrombus genera-
tion as well as elevated clot amplification. Furthermore, a 
statistical trend was seen in the A-angle value indicating 
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that the rate of fibrin build-up and crosslinking is ele-
vated in diabetes, which can be attributed to an elevated 
thrombin burst in compared to the healthy aged controls. 
Similarly, a significantly increased maximum clot ampli-
tude (MA) in conjunction with elevated maximal rate of 
thrombus generation (MRTG) observed in T2DM indi-
cates the formation of a more rigid and stable clot in a 
significantly accelerated manner. Finally, the significant 
change in the total thrombus generation (TTG) further 
indicates the overall elevated strength and stability of the 
diabetic clots in comparison to that of the healthy con-
trols. The noted aberrant parameters indicate a hyperco-
agulable state in T2DM which has been previously noted 
in literature [71–73, 75]. These structural changes in the 
diabetic fibrin clots were also confirmed using SEM. In 
future, a comprehensive analysis on fibre structure and 
thickness measurement could add valuable informa-
tion, particularly with regards to how fibre structure and 
thickness may relate to a compromised lytic potential.
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The T2DM clots were rich in dense matted depos-
its, previously shown to correspond to amyloidogenic 
regions in the fibrin clots [75]. Furthermore, multiple 
fine fibrin fibres meshes were noticed in the diabetic clots 
compared to the controls. These findings align with pre-
vious evidence. The TEG and SEM results taken together 
with the circulating biomarker results (Fig. 2) point to a 
dysregulated circulating molecule presence that might 
have a direct effect on the development of abnormal 
clot structure and formation, resulting in a dysregulated 
coagulation system in T2DM.
Although evidence involving the aberrant role of 
inflammatory mediators in both communicable and 
non-communicable disease is indisputable, limited evi-
dence exists regarding the role of inflammatory cytokines 
in coagulation and fibrinolytic processes in T2DM. 
Researchers have predominantly investigated relation-
ships through various cell culture models of LPS-induced 
disease, relating to bacterial and viral infection on 
hemodynamic processes (see Additional file  1: Tables). 
Here, we confirm the physiological effect of dysregu-
lated circulating cytokines, and confirm that their pres-
ence is accompanied by a hypercoagulable phenotype. 
These dysregulated circulating cytokines therefore are 
a direct link between hypercoagulation and inflamma-
tion and it manifests in T2DM as a bidirectional rela-
tionship between (hyper)coagulation and inflammation. 
We provide evidence that the majority of inflammatory 
molecules were elevated in T2DM patients relative to 
healthy controls a phenomenon that is consistent with 
established literature (see Additional file  1: Tables S1) 
particularly with regards to their role in T2DM patho-
genesis. Many of the biomarkers studied here, are also 
known to act as ligands to e.g. platelet, as well as red 
blood cell (RBC) membrane receptors; examples include 
e.g. IL-1β, IL-6 and IL-8, where their binding to platelet 
receptors are known to activate various inflammatory 
pathways, resulting in platelet hyperactivity, aggregation 
and spreading, as well as contributing to the circulating 
inflammatory milieu [76, 77]. Furthermore, the presence 
of p-selectin, which is a prominent platelet product, is 
directly indicative of dysregulated platelet aggregation 
and activation, which can directly drive and actively par-
ticipate in the development of hypercoagulation [78].
A somewhat salient finding of the present study 
involves the increased levels of anti-inflammatory 
cytokines (IFN-α, IL-10, IL-4, IL-13) observed in T2DM 
patients relative to controls. These molecules are known 
anti-inflammatory cytokines, but their increased pres-
ence in our T2DM sample might be indicative of the 
very complex interplay between these molecules and 
their pro-inflammatory counterparts; where the ele-
vated expression of anti-inflammatory cytokines might 
point to their part as compensatory and counter regula-
tory molecules, that might aim to limit damage by pro-
inflammatory environment. Notably, evidence of elevated 
anti-inflammatory molecules in disease is by no means 
an anomaly, and has been observed and interpreted in 
previous research, however not in the context of T2DM. 
Consistent with this, a study on IL‐10 and risk of cardio-
vascular events observed circulating IL‐10 concentra-
tions to be positively associated with pro-inflammatory 
mediators including CRP and IL‐6 [79]. Additionally, ele-
vated pro-inflammatory cytokines, such as IL-6 and TNF-
α, have been observed to accompany  anti-inflammatory 
IL-10 production  in certain inflammatory conditions to 
compensate for inflammation [80]. The physiological role 
of IL-10 is to limit the inflammatory response by limit-
ing pro-inflammatory cytokine production and suppress-
ing pro-inflammatory T-helper 1 cells natural killer cells 
and macrophages activity [81]. Thus, it stands to reason 
that the anti-inflammatory response serves to limit pro-
inflammatory activity  mediated by elevated pro-inflam-
matory cytokines, thus elicitinga counter-regulatory role 
to inflammatory stimuli. We also would like to point out 
that both our kits, analyzed s-ICAM-1. The Procarta 
panel is a Luminex system, which uses a fluorescent 
bead system and a 2-LOG ratio, while the MSD panel 
uses a 4-LOG ratio. The detection ranges are also as fol-
lows: MSD (ICAM-1: 1.94–32,700  pg  mL−1) and Pro-
carta Luminex (ICAM-1: 151.85–622,000 pg mL−1). Our 
Fig. 5 Summary of the circulating biomarkers and hypercoagulation 
markers of T2DM. Diagram created using BioRender (https ://biore 
nder.com/)
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Luminex panel analysis showed a p value of 0.79, while 
our MSD panel analysis showed a P-value of 0.009. Tak-
ing this into account, we also suggest that the choice of 
panels and their sensitivity should be considered if they 
are used in a clinical setting. Figure 5 shows a summary 
diagram of the main findings of this paper.
Conclusion
In conclusion, T2DM is an extremely complex and mul-
tifaceted inflammatory disease. These results point to 
the fact that a personalized approach urgently needs 
to be followed when planning treatment and tracking 
the patient heath status after embarking on a treatment 
regime, and that looking to novel biomarkers might be 
crucial. Our patient sample were all on various medica-
tion interventions, but still their biomarker profiles are 
significantly different from that of healthy individuals. 
Diabetes management following a uniform treatment 
algorithm is often associated with progressive treat-
ment failure and development of diabetic complications 
[82]. Importantly, a better risk stratification and more 
precise options for treatment need to be developed and 
included in clinical practice guidelines [83]. The growing 
T2DM patient numbers discussed earlier in this paper, 
suggest that the only way forward is to follow innovative 
approaches to curb the pandemic we are facing. Perhaps 
the only option will be to follow an individualized preci-
sion medicine approach by using a panel of biomarkers 
and combining it with e.g. thromboelastography as part 
of a regular clinical evaluation. By tracking the inflam-
matory status of T2DM using various biomarkers, before 
and after embarking on a treatment regime, might allow 
for a more focussed treatment regime.
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contributes towards the development, and/or pathogenesis of T2DM.
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